Skip to main content
Figure 1 | Molecular and Cellular Therapies

Figure 1

From: Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma

Figure 1

Miravirsen inhibits miR-122. a, Mir-122 binds two target sites in the HCV 5′ non-coding region and promotes HCV propagation. b, Miravirsen, a modified oligonucleotide complementary to miR-122 sequences, binds and sequesters mature miR-122, resulting in the functional inhibition of miR-122. Miravirsen also binds to the stem-loop structure of pri- and pre-miR-122 and inhibits the maturation of miR-122.

Back to article page

Molecular and Cellular Therapies

ISSN: 2052-8426

Contact us